IVA - Inventiva's odiparcil nabs accelerated review in U.S. for a rare genetic disorder

The FDA has designated Fast Track status to Inventiva's (IVA) odiparcil for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.The Fast Track program facilitates the development and expedite the regulatory review and potential approval of drug candidates.Odiparcil has been granted Orphan Drug Designation by the FDA and the European Medicines Agency, as well as FDA Rare Pediatric Disease Designation for the same indication.

For further details see:

Inventiva's odiparcil nabs accelerated review in U.S. for a rare genetic disorder